Related Experiment Video

Updated: Feb 5, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.9K

Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma

Philip Eliades1,2,1,2, Keith T Flaherty3,3, Hensin Tsao1,1

  • 1Wellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

Melanoma Management
|September 8, 2018
PubMed

Insights

Targeted therapies for advanced melanoma show promise by targeting MAPK signaling. However, suboptimal response rates and lack of treatments for many patients necessitate further research into novel molecularly targeted therapies.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Cancer genetics and molecular biology advancements have transformed advanced melanoma treatment.
  • Targeted therapies, particularly those inhibiting MAPK pathway signaling, benefit select patients.
  • Current treatments face limitations including suboptimal response rates and duration, and a lack of options for many melanoma types.

Purpose of the Study:

  • To review the current status of molecularly targeted therapies for melanoma.
  • To explore the future potential of these therapies.
  • To examine therapies targeting significant oncogenic signaling pathways in melanoma.

Main Methods:

  • Review of preclinical and clinical studies on targeted therapies for melanoma.
  • Analysis of US FDA-approved therapies targeting MAPK pathway signaling.
  • Examination of novel targeted therapies for molecularly defined melanomas.

Main Results:

  • Vemurafenib, a BRAF V600E inhibitor, approved in 2011, spurred significant research.
  • Targeted therapies have revolutionized treatment for specific molecularly defined melanomas.
  • Despite progress, response rates and duration remain suboptimal for many patients.

Conclusions:

  • Molecularly targeted therapies represent a significant advancement in advanced melanoma treatment.
  • Further research is crucial to overcome current limitations and develop new therapies.
  • Future efforts should focus on a broader range of molecular targets and pathways to improve patient outcomes.
Keywords:
KITMAPK pathwayPI3K pathwayTCGAmelanomaoncogene-directed therapysmall molecule inhibitortargeted therapy

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.2K

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
613
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.5K
Molecules and Compounds02:38

Molecules and Compounds

Atoms and Molecules
68.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
544